Oppenheimer Reiterates Outperform on ArriVent BioPharma, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for ArriVent BioPharma (NASDAQ:AVBP) and increased the price target from $35 to $39.
September 10, 2024 | 3:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated its Outperform rating for ArriVent BioPharma and increased the price target from $35 to $39, indicating positive analyst sentiment.
The reiteration of an Outperform rating and an increased price target from a reputable analyst can boost investor confidence, potentially leading to a short-term increase in AVBP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100